# EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

> **NCT03341494** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 128 (estimated)

## Conditions studied

- NSCLC Stage IV
- Chemotherapy Effect

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT03341494
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-01
- **Primary completion:** 2019-11-01
- **Final completion:** 2020-11-01
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03341494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03341494, "EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03341494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*